<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592031</url>
  </required_header>
  <id_info>
    <org_study_id>XM17-02</org_study_id>
    <secondary_id>2008-005756-24</secondary_id>
    <nct_id>NCT02592031</nct_id>
  </id_info>
  <brief_title>Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women</brief_title>
  <official_title>An Open, Randomized, Two-way Cross-over Phase I Study to Compare the Bioavailability, Safety and Tolerability of Single s.c. Doses of 300 IU XM17 With 300 IU Gonal-f® in 36 Healthy, Down-regulated Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merckle GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to demonstrate the bioequivalence of single subcutaneous doses of XM17
      and Gonal-f® in a confirmatory design. Furthermore, safety and tolerability will be assessed
      in human healthy female subjects. Only female subjects will be included in the study to reach
      the objectives of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of single dose pharmacokinetics (Cmax)</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>XM17 and Gonal-f® tested statistically for bioequivalence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of single dose pharmacokinetics (AUC0-t)</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>XM17 and Gonal-f® tested statistically for bioequivalence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics AUC0-∞</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Area under the XM17 / Gonal-f® concentration time curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics AUC0-168h</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Area under the XM17 / Gonal-f® concentration time curve from time 0 to 168 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Cmax,obs</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Maximum XM17 / Gonal-f® concentration determined during the interval of sample taking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Tmax</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Time to maximum XM17 / Gonal-f® concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics λZ</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Apparent terminal elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics t1/2</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Apparent terminal elimination half life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics CL/F</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Serum clearance after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Vz/F</measure>
    <time_frame>Pre-dose at -10 min, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 hours post-dose</time_frame>
    <description>Volume of Distribution during the terminal phase after extravascular administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events</measure>
    <time_frame>Signing of informed consent to final data collection (27 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>XM17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XM17 will be administered by 1 mL syringes in graduated steps of 0.01 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-f®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gonal-f® will be provided in pens with integrated vials of 0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoladex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoladex® 3.6 mg will be administered by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XM17</intervention_name>
    <description>300 IU corresponds to an injection volume of 0.5 mL.</description>
    <arm_group_label>XM17</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-f®</intervention_name>
    <description>300 IU corresponds to an injection volume of 0.5 mL.</description>
    <arm_group_label>Gonal-f®</arm_group_label>
    <other_name>follitropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoladex®</intervention_name>
    <description>3.6 mg</description>
    <arm_group_label>Zoladex®</arm_group_label>
    <other_name>goserelin acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed written informed consent

          -  Healthy female subjects of any racial origin

          -  18-39 years at the time of screening

          -  Body mass index (BMI) between 18-29 kg/m2 and a body weight of ≥ 50 kg

          -  Use of oral contraceptives for contraceptive purposes only and not for regularization
             of menstrual cycle, for at least 3 months

          -  Normal uterus and two functioning ovaries

          -  Agrees to use an adequate method of contraception during the study

          -  Non-smoking or moderate smokers of &lt; 10 cigarettes a day

        Exclusion Criteria:

          -  Pregnancy

          -  Polycystic ovary syndrome, impaired ovarian function, severe endometriosis class III
             or IV, submucosal myoma uteri

          -  History of endocrine abnormalities with treatment within the last six months.

          -  Contraindications for the use of gonadotropins and goserelin

          -  Breast-feeding or being within a period of 2 months after delivery or abortion.

          -  Use of an injectable hormonal contraceptive within a period of 6 months prior to
             screening

          -  Treatment in the previous three months with any drug known to have a well-defined
             potential for toxicity to a major organ
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

